A Phase 4 interventional study of triamcinolone acetonide extended-release injectable suspension; TCA-ER and Triamcinolone Acetonide- Immediate Release;TCA-IR in Osteoarthritis, Knee and Diabetes Mellitus, Type 2, sponsored by University of Kansas Medical Center. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.
Sponsored by University of Kansas Medical Center · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing Triamcinolone Acetonide in Osteoarthritis, Knee — 2 open to participants now, 2 under way, 1 of them phase 3. Triamcinolone Acetonide · Osteoarthritis, Knee.
Among the 18 studies testing Triamcinolone Acetonide in Osteoarthritis, Knee, this one is the 7th largest by planned enrollment, is the only one that started in 2024, is one of 5 in phase 4, and was the 17th registered.
3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.
Browse Osteoarthritis, Knee studies →2 of the 18 studies testing Triamcinolone Acetonide in Osteoarthritis, Knee are open now, in 1 country. Recruiting first, the newest first:
Walter Reed National Military Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →
Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.
This study: 40 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 4 · Phase 4 5
First in 2012; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is above the median of 68 across 2,719 interventional studies indexed under Osteoarthritis, Knee.
Median enrollment 73 across the 18 interventional studies. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 18 have an industry lead sponsor. The 9 most frequent:
University of Kansas Medical Center is the lead sponsor of 493 studies on the registry; 111 are open to participants now.
Of its 38 completed or terminated interventional studies of FDA-regulated products, 24 (63%) have results posted.
University of Kansas Medical Center has 7 studies filed under Osteoarthritis, Knee — fewer than ten, so there is no comparison to draw.
2 of the studies testing Triamcinolone Acetonide in Osteoarthritis, Knee that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07151417Phase 3Walter Reed National Military Medical CenterUse of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery. | 2027-08-31 |
| NCT06478186University of Kansas Medical CenterKnee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes | 2026-12-16 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies testing Triamcinolone Acetonide in Osteoarthritis, Knee, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A Phase 2 Randomized Study to Evaluate the Effects of triamcinolone acetonide extended-release (TA-ER; Zilretta) vs. triamcinolone acetonide immediate-release (TA-IR; Kenalog) on Blood Glucose Levels in Diabetic Subjects with Knee Osteoarthritis. Subjects should have Type 2 Diabetes Mellitus (T2DM) with HbA1C ≤9 that is managed without insulin and have been diagnosed with symptomatic unilateral or bilateral osteoarthritis (OA) of the knee, based on clinical and radiological criteria (if bilateral, then a target knee will be selected).Total study duration for individual subject will be about 4 months, which includes 3 weeks of Screening period, 10 days of pretreatment phase, treatment day, and 12 weeks of post-treatment period.
Protocol Title: A Randomized, Double-blind, Active-controlled Study to Evaluate the Effects of ZILRETTA (Triamcinolone Acetonide-Extended Release) and TA-IR (Triamcinolone Acetonide-Immediate Release) on Blood Glucose Levels in Subjects with Osteoarthritis of the Knee and Type 2 Diabetes Mellitus Brief Title: Zilretta Diabetic Knee OA Regulatory Agency Identifier Number(s): IND 111325 Test Product, Dose, Mode of Administration, and Lot Number Name: ZILRETTA (triamcinolone acetonide extended-release injectable suspension; TA-ER) Active ingredient: Extended-release formulation of TA in 75:25 poly (lactic-co-glycolic) acid (PLGA) microspheres Dosage: Nominal 32 mg TA, intra-articular (IA) injection, administered as a 5 mL injection Mode of Administration: IA Knee Injection Reference Product, Dose, Mode of Administration, and Lot Number Name: Kenalog®-40 (triamcinolone acetonide injectable suspension) Active Ingredient: Triamcinolone Acetonide- Immediate Release (TA-IR) Dosage: 40 mg/mL, IA, administered as a 1 mL Injection: TA-IR Mode of Administration: IA Knee Injection Current Indication: extended-release synthetic corticosteroid indicated as an IA injection for the management of osteoarthritis pain of the knee.
Study Population and Number of Study Subjects: Subjects with Type 2 Diabetes Mellitus (T2DM) with HbA1C ≤9 that is managed without insulin and have been diagnosed with symptomatic unilateral or bilateral osteoarthritis (OA) of the knee, based on clinical and radiological criteria (if bilateral, then a target knee will be selected) Approximately 120 subjects (1:1 randomization, 60 ZILRETTA and 60 TA-IR) will be enrolled for this study.
Note: Subject is considered enrolled, if subject meets initial eligibility criteria and is randomized to a treatment arm.
Study Duration for Subjects:
Total study duration for individual subject will be about 4 months, which includes a 3-week Screening period, 10 days pretreatmentperiod, treatment day, and a 12-week post-treatment period.
Overall Study Design:
This randomized clinical trial will include male and female subjects ≥40 years of age, with known history of T2DM and symptomatic unilateral or bilateral OA of the knee. Eligible subjects must be on stable doses of oral and/or injectable (non-insulin) pharmacological agents (e.g. GLP-1 agonists) for at least 3 months prior to the study screening and after the IA injection till EOS and have hemoglobin A1c (HbA1c) levels ≤9% at Screening. Subjects on current insulin treatment will be excluded.
After signing informed consent, subjects will be screened and a total of 120 qualified subjects with T2DM will be randomized to 1 of the 2 treatment groups (1:1). Randomized subjects will be treated with either 32 mg ZILRETTA (60 subjects) or 40 mg TA-IR (60 subjects). Subjects who fail to meet eligibility criteria may be re-screened once at the discretion of Principal Investigator (PI) after documenting the rationale for any re-screening decision. Subjects who meet all eligibility criteria but are found to have insufficient BG data at their Day 1 visit (ie, missing CGM data ≥ 30%) may repeat the full 7-day pretreatment phase at the discretion of the PI.
BG Monitoring and Management of T2DM During the Trial After a Screening visit, BG levels in each subject will be measured using a CGM device, for at least 10 days pre-injection (pretreatment period) and for at least 10 days postinjection (post-treatment). The final 10 days of the pretreatment period will be also considered as Baseline for BG control.
Subjects and the assessor responsible for subject's clinical assessments and safety monitoring will be blinded throughout the study to both treatment assignments. Subjects will be blinded to the glucose readings, so as not to influence behaviors that could alter blood glucose outcome measures. However, study endocrinologists will monitor subjects' glucose readings. The study will involve between 6-12 outpatient visits (depending on whether selected for salivary cortisol tesing) and up to 4 phone visits that will include Screening, a Pretreatment visit (Day -14 where the CGM sensor will be placed to initiate study BG data collection), Day 1 (Baseline and treatment), and 2 Posttreatment visits (Days 43, and 85). CGM data will be continuously collected from the treatment visit through Day 15. On Day 15, subjects will remove the CGM sensor. Day 85 will be end-of-study (EOS) visit.
A subset of subjects will will return saliva for cortisol testing at baseline and on Days 1, 2, 3, 7, 14, 21, 42, 72, and 90 following treatment.
After IA treatment subjects are should not adjust their diabetes medications and Baseline physical activity should remain unchanged.
Intermediate-acting glucocorticoids (GCs) represent the most commonly prescribed steroid agents. In general, during the course of chronic GC treatment, GCs may require frequent dose adaptations that result in more intensive altered requirements of glucose-lowering therapies. However, since the selected diabetic population will receive a single IA injection, large glucose fluctuations as experienced with chronic GC treatments are not expected. Baseline glucose medication dosage will not change. Subjects' BG control will be monitored in coordination with study endocrinologist.
The analyses of primary and secondary endpoints will be conducted mainly based on CGM device.
Hypothalamic-Pituitary-Adrenal (HPA) Axis Evaluation Treatment with GCs represents one of the most frequent causes of secondary adrenal insufficiency. When GCs are used at supraphysiologic doses, HPA axis suppression causes adrenal glands' inability to produce sufficient cortisol response to abrupt treatment cessation (Nicolaider et al, 2018). To avoid HPA axis suppression, it is recommended not to exceed 3 GC IA injections per year with a minimum of 30 days between (Johnston et al, 2015). Recovery of the HPA axis to Baseline normally occurs within 1-4 weeks but can be longer in consideration of the dose and frequency of injections (Habib, 2009). However, after single IA dose of GC injection recovery after 1-2 weeks was observed in most of the patients (Mader et al, 2005). Thus, an initial 90-day salivary cortisol assessment in a subset of this trial population should suffice. An 8 AM salivary cortisol test will be completed at baseline and 1, 2, 3, 7, 14, 21, 42, 72, and 90 day following baseline to evaluate the effect of Zilretta and TA-IR on the HPA axis and recovery time.
Intra-Articular Injection On Day 1 (Treatment Day), IA injections will be administered by the assigned blinded, trained injector, who has experience in the administration of IA injections and has been trained on study administration procedures. Injection into the knee joint will be performed with/without ultrasound guidance.
Subjects will be advised to avoid strenuous or prolonged weight-bearing activities for approximately 24 to 48 hours following the injection. If the subject has an immediate reaction (eg, tenderness, increased pain, swelling, effusion, and/or decreased mobility of the index knee), the subject should be treated according to clinical guidelines and physician experience and judgment.
Pain will be assessed by NRS evaluating Worst Daily Knee Pain Intensity and Average Daily Knee Pain, which will be recorded in the pain Diary per the Schedule of Assessments (Table 1) and reviewed at each study visit. Physical performance will be assessed with OARSI recommended10 physical performance measures (40m walk time and stair ascent time) along with patient-reported physical function (KOOS-PS) and quality of life (KOOS-QoL) at baseline and at intervals following IA injection.
Internal Safety Review Subject safety will be monitored by an endocrinologist. The endocrinologist will review, at a minimum, safety, tolerability, and pharmacodynamic (PD) data on ongoing basis. All members will be blinded to the treatment.
The study PI and study endocrinologist will review all SAEs on an ongoing basis (ie, as the events are reported). The study PI is responsible for temporarily halting the study if the type, frequency, or seriousness/severity of such events suggests a potential threat to the safety of the study subjects. The safety review team will meet semiweekly or monthly depending upon recruitment rate. Ad hoc meetings may be scheduled as necessary.
The study PI may pause/stop the study if any of the following occurs:
Any deaths, regardless of causality. Non-fatal SAEs in 12 subjects (≥10% of total subject population) where a clear unrelated causality is not readily apparent.
Grade 3 or higher AEs in 12 subjects (≥10% of total subject population) that are clinically significant (Exception: PD parameters or related changes to labs and symptoms will not be considered as AEs) In the event that any of the preceding criteria occurs, enrollment will be paused during the review. If a pausing/stopping rule is met, a decision will be made whether to resume the enrollment.
Case unblinding may be performed for above reviews if necessary and documented accordingly.
Clinical Safety Assessments The index knee assessment will be performed by the designated assessor at the visits indicated in the Schedule of Assessments (Table 1). The index knee will be assessed for injection site reaction, joint effusion, range of motion and presence of Baker's cyst.,. After Day 1 Baseline, new clinically significant findings or findings that worsen from the subject's Baseline knee condition will be recorded as an adverse event (AE).
PD parameters measured during this study such as BG levels (CGM or fingerstick), insulin consumption, HPA axis evaluation parameters, and hyperglycemia symptoms will not be reported as AEs.
Safety evaluations will be based on the assessment of AEs occurring after the initiation of investigational product (IP) on Day 1 through the EOS Visit (Day 85). Results of clinical safety assessments are to be recorded in the subject's medical records and transcribed to the appropriate electronic case report form (eCRF), including the AE eCRF for clinically significant findings.
AEs will be coded using CTCAE v.5. Incidences (number and percent) of TEAEs, those events that started after dosing or worsened in severity after dosing, will be presented by treatment group. Incidences of TEAEs will also be presented by maximum severity and relationship to IP. Safety laboratory investigations and vital signs will be summarized descriptively by time point collected along with changes from Baseline assessments.
Statistical Methods Descriptive statistics (n, mean, standard deviation [SD], median, minimum, and maximum) will be calculated by treatment group and time point for continuous variables. Frequencies and percentages will be presented by treatment group for categorical and ordinal variables.
The primary endpoint of change in percent of time in TAR will be analyzed with linear regression. Both models will have a fixed effect for treatment group along with covariates (eg, the mean of the pretreatment BG values, BMI).
A step-down testing procedure will be employed for primary and key secondary endpoints, with sequential testing proceeded as long as p \< 0.05. Key secondary endpoints and order of testing will be specified in the SAP (Holm, S., 1979. A simple sequentially rejective multiple test procedure. Scandinavian journal of statistics, pp.65-70).
Study Sample Size A prior Phase II study found a difference of approximately 15 percentage points in TAR for TA-ER vs standard triamcinolone acetonide crystalline suspension (TAcs) (\~35% for TA-ER vs. 50% for TAcs). 120 subjects will provide >80% power to detect an effect size of 10 percentage points, assuming a standard deviation of 18. The primary outcome will be measured 72 hours after treatment by a sensor automatically uploading the data, thus we expect few dropouts are expected.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
1. Written consent to participate in the study. 2. Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions.
3. Male or female ≥40 years of age. 4. Females with negative pregnancy test, who are not breastfeeding and have no intention to become pregnant during the time from screening through EOS.
5. Type 2 DM for at least 1 year prior to Screening. 6. Currently being treated with injectable (except insulin) and/or oral antidiabetic agents with stable doses for at least 1 month prior to Screening.
7. 6.5-9% (in past 8 weeks). 8. Estimated (eGFR) ≥50 mL/min/1.73 m2. (in past 8 weeks) 9. Triglycerides \<500 mg/dL (in past 8 weeks) 10. Painful symptoms associated with OA of the knee for ≥6 months prior to Screening (NRS of 4-9 during most of the 30 days prior to enrollment).
11. Currently meets modified ACR criteria (clinical and radiological) for OA (Altman et al, 1986) as follows:
At least 1 of the following:
Osteophytes 12. Index knee pain more than 15 days over the last month (as reported by the subject).
13. Kellgren-Lawrence Grade 2-4. 14. Willingness to wear a CGM device uninterrupted for 24 hours per day throughout the required time during the study and comply to the correct use requirements of CGM throughout the trial and perform self BG checks as directed.
15. Adequate BG data collected during the pretreatment phase (Day -10 through Day -1) ≥70% data available.
Exclusion Criteria:
Disease-related Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Name: ZILRETTA (triamcinolone acetonide extended-release injectable suspension; TA-ER) Active ingredient: Extended-release formulation of TA in 75:25 poly (lactic-co-glycolic) acid (PLGA) microspheres Dosage: Nominal 32 mg TA, intra-articular (IA) injection, administered as a 5 mL injection Mode of Administration: IA Knee Injection
Drug: triamcinolone acetonide extended-release injectable suspension; TCA-ER
Name: Kenalog®-40 (triamcinolone acetonide injectable suspension) Active Ingredient: Triamcinolone Acetonide- Immediate Release (TA-IR) Dosage: 40 mg/mL, IA, administered as a 1 mL Injection: TA-IR Mode of Administration: IA Knee Injection
Drug: Triamcinolone Acetonide- Immediate Release;TCA-IR
Mode of Administration: IA Knee Injection Nominal 32 mg TCA, intra-articular (IA) injection, administered as a 5 mL injection
Mode of Administration: IA Knee Injection Triamcinolone Acetonide- Immediate Release (TCA-IR)
Percent of time spent with blood glucose >180 mg/dL
To assess continuous glucose monitoring (CGM) patterns for Time Above Range (TAR) levels of the upper limit of the recommended target range (glucose levels \>180 mg/dL) from Baseline to 72 hours following a single IA injection of 32 mg of ZILRETTA relative to 40 mg of TA-IR.
Time frame: The primary outcome will be measured up to 72 hours after treatment by a sensor automatically uploading the data
Area under the curve (AUC) for cortisol levels
To characterize HPA axis suppression from Baseline until the end-of-study comparing ZILRETTA vs TA IR.
Time frame: From baseline until the end-of-study (Day 85).
Percentage of time spent with blood glucose above >180 mg/dL
To characterize the number of subjects and percentage of time spent in TAR from Baseline throughout the10 days comparing ZILRETTA vs TA-IR.
Time frame: From baseline throughout 10 days follow-up.
Number of blood glucose peaks ≥250 mg/dL
To characterize number of peaks ≥250 mg/dL per subject from Baseline throughout the 10 days comparing ZILRETTA vs TCA-IR.
Time frame: From baseline throughout 10 days follow-up
Change in 40m walk time
To determine the extent to which intra-articular (IA) injection of Zilretta vs. TA-IR in patients with dual diagnosis of T2DM and knee OA improves physical performance (OARSI recommended physical performance measures- timed 40m walk).
Time frame: Between baseline and 12 weeks.
Change in stair climb time
To determine the extent to which intra-articular (IA) injection of Zilretta vs. TA-IR in patients with dual diagnosis of T2DM and knee OA improves physical performance (OARSI recommended physical performance measures- timed stair climb).
Time frame: Between baseline and 12 weeks.
Change in patient-reported physical function (KOOS-PS)
To determine the extent to which intra-articular (IA) injection of Zilretta vs. TA-IR in patients with dual diagnosis ofT2DM and knee OA improves physical function (KOOS-PF). 100 point scale on which 100 is best and 0 is worst.
Time frame: Between baseline and 12 weeks.
Change in quality of life (KOOS-QoL)
To determine the extent to which intra-articular (IA) injection of Zilretta vs. TA-IR in patients with dual diagnosis ofT2DM and knee OA improves quality of life (KOOS-QoL). 100 point scale on which 100 is best and 0 is worst.
Time frame: Between baseline and 12 weeks
Change in worst daily knee pain intensity
To determine the worst daily knee pain intensity score in the index knee (0-10 Numeric Pain Rating Scale \[NRS\]). 100 point scale on which 100 is worst pain and 0 is no pain.
Time frame: From baseline to Weeks 6 and 12
Change in Average Daily Pain
To determine the average daily pain score in the index knee (0-10 NRS). 10 point scale on which 0 is no pain and 10 is worst pain imaginable.
Time frame: From baseline to each follow-up week from 1 to 12 weeks after treatment
Effect of hyperglycemia on fatigue
To assess the acute effects of hyperglycemia on fatigue for 32 mg of ZILRETTA relative to 40 mg of TCA-IR.
Time frame: From baseline to time periods of 0 to 24 hours (Days 1-2); 0 to 48 hours (Days 1- 3); and 0 to 72 hours (Days 1-4), for ZILRETTA relative to TCA-IR. Diabetes Symptom Checklist - Revised (DSC-R) is scored from a low of 1 to a high of 5.
Effect of hyperglycemia on cognition
To assess the acute effects of hyperglycemia on cognition for 32 mg of ZILRETTA relative to 40 mg of TCA-IR.
Time frame: From baseline to time periods of 0 to 24 hours (Days 1-2); 0 to 48 hours (Days 1- 3); and 0 to 72 hours (Days 1-4), for ZILRETTA relative to TCA-IR. Diabetes Symptom Checklist - Revised (DSC-R) is scored from a low of 1 to a high of 5.
Incidence of Treatment-Emergent Adverse Events (TEAEs) and SAEs
To assess the safety and general tolerability of a single IA injection of 32 mg of ZILRETTA relative to 40 mg of TCA-IR.
Time frame: From baseline to Day 30
Plan to share: No
Started Aug 2024 (actual). Primary completion is estimated for Dec 2026, 28 months after the start.
Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's planned 28 months is above that.
Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide
University of Kansas Medical Center →